Valuation Eurofins Scientific SE London S.E.
Stocks
0MV5
FR0014000MR3
Biotechnology & Medical Research
|
Market Closed -
London S.E.
11:30:00 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 75.20 EUR | +0.80% |
|
-2.46% | +20.72% |
| 10-02 | Eurofins Completes Sale of MET Labs Business | MT |
| 10-01 | UL Solutions Completes Acquisition of Eurofins' Electrical, Electronics Business | MT |
Company Valuation: Eurofins Scientific SE
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 20,893 | 12,900 | 11,336 | 9,273 | 11,036 | 12,996 | - | - |
| Change | - | -38.26% | -12.13% | -18.2% | 19.02% | 17.75% | - | - |
| Enterprise Value (EV) 1 | 23,132 | 15,739 | 14,041 | 12,269 | 14,677 | 16,362 | 16,029 | 15,792 |
| Change | - | -31.96% | -10.79% | -12.62% | 19.63% | 11.48% | -2.03% | -1.48% |
| P/E | 27.8x | 22.2x | 45.4x | 26.9x | 28x | 25x | 19.7x | 16.6x |
| PBR | 4.49x | 2.7x | 2.24x | 1.73x | 2.56x | 2.77x | 2.52x | 2.33x |
| PEG | - | -1x | -0.8x | 0.7x | 1.3x | 0.7x | 0.7x | 0.9x |
| Capitalization / Revenue | 3.11x | 1.92x | 1.74x | 1.33x | 1.51x | 1.72x | 1.64x | 1.53x |
| EV / Revenue | 3.44x | 2.34x | 2.16x | 1.77x | 2.01x | 2.17x | 2.02x | 1.86x |
| EV / EBITDA | 12.2x | 10.4x | 10.3x | 7.91x | 8.94x | 9.33x | 8.45x | 7.67x |
| EV / EBIT | 15.7x | 15.2x | 16.7x | 12.1x | 13.6x | 14.4x | 12.8x | 11.4x |
| EV / FCF | 22.8x | 23.2x | 29.6x | 15.3x | 16.7x | 20.3x | 18.3x | 16.4x |
| FCF Yield | 4.39% | 4.3% | 3.38% | 6.53% | 5.97% | 4.93% | 5.46% | 6.11% |
| Dividend per Share 2 | 1 | 1 | 0.5 | 0.5 | 0.72 | 0.8027 | 0.9094 | 0.9603 |
| Rate of return | 0.92% | 1.49% | 0.85% | 1.01% | 1.15% | 1.07% | 1.21% | 1.28% |
| EPS 2 | 3.91 | 3.02 | 1.3 | 1.83 | 2.23 | 2.999 | 3.796 | 4.504 |
| Distribution rate | 25.6% | 33.1% | 38.5% | 27.3% | 32.3% | 26.8% | 24% | 21.3% |
| Net sales 1 | 6,718 | 6,712 | 6,515 | 6,951 | 7,296 | 7,537 | 7,944 | 8,475 |
| EBITDA 1 | 1,902 | 1,513 | 1,364 | 1,552 | 1,641 | 1,754 | 1,897 | 2,059 |
| EBIT 1 | 1,473 | 1,037 | 842 | 1,017 | 1,079 | 1,133 | 1,250 | 1,383 |
| Net income 1 | 783 | 606 | 310 | 406 | 475 | 530.9 | 659.7 | 817.4 |
| Net Debt 1 | 2,239 | 2,839 | 2,705 | 2,996 | 3,641 | 3,366 | 3,034 | 2,796 |
| Reference price 2 | 108.80 | 67.06 | 58.98 | 49.31 | 62.40 | 74.86 | 74.86 | 74.86 |
| Nbr of stocks (in thousands) | 192,035 | 192,365 | 192,194 | 188,049 | 176,864 | 173,599 | - | - |
| Announcement Date | 2/22/22 | 3/1/23 | 2/27/24 | 1/30/25 | 1/29/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.73x | 7.71x | 15.48x | 1.37% | 74.16B | |
| 29.82x | 8.57x | 26.7x | 0.04% | 57.39B | |
| 32.98x | 5.93x | 17.77x | 0.98% | 47.64B | |
| -21.31x | 230.81x | -22.97x | -.--% | 44.29B | |
| 33.26x | 3.23x | 13.97x | -.--% | 42.5B | |
| 46.77x | 5.41x | 29.66x | -.--% | 40.71B | |
| 27.63x | 7.93x | 20.48x | 0.41% | 30.97B | |
| 32.99x | 7.05x | 18.3x | -.--% | 28.53B | |
| -15.1x | 5.68x | -7.14x | -.--% | 24.34B | |
| Average | 20.98x | 31.37x | 12.47x | 0.31% | 43.39B | |
| Weighted average by Cap. | 22.27x | 32.04x | 13.55x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ERF Stock
- 0MV5 Stock
- Valuation Eurofins Scientific SE
Select your edition
All financial news and data tailored to specific country editions
